JP5990511B2 - 血管新生に基づく眼障害の処置のための抗ｃｄ１６０特異的抗体 - Google Patents

血管新生に基づく眼障害の処置のための抗ｃｄ１６０特異的抗体 Download PDF

Info

Publication number
JP5990511B2
JP5990511B2 JP2013511702A JP2013511702A JP5990511B2 JP 5990511 B2 JP5990511 B2 JP 5990511B2 JP 2013511702 A JP2013511702 A JP 2013511702A JP 2013511702 A JP2013511702 A JP 2013511702A JP 5990511 B2 JP5990511 B2 JP 5990511B2
Authority
JP
Japan
Prior art keywords
antibody
scfv
disease
combined preparation
conservative
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP2013511702A
Other languages
English (en)
Japanese (ja)
Other versions
JP2013528607A (ja
JP2013528607A5 (enExample
Inventor
ルブーティエ，フィリップ
ベンスーサン，アルマン
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Mablife SAS
Original Assignee
Mablife SAS
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Mablife SAS filed Critical Mablife SAS
Publication of JP2013528607A publication Critical patent/JP2013528607A/ja
Publication of JP2013528607A5 publication Critical patent/JP2013528607A5/ja
Application granted granted Critical
Publication of JP5990511B2 publication Critical patent/JP5990511B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Dermatology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Emergency Medicine (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
JP2013511702A 2010-05-28 2011-05-27 血管新生に基づく眼障害の処置のための抗ｃｄ１６０特異的抗体 Expired - Fee Related JP5990511B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US34927110P 2010-05-28 2010-05-28
US61/349,271 2010-05-28
PCT/EP2011/058777 WO2011147984A1 (en) 2010-05-28 2011-05-27 Anti-cd160 specific antibodies for the treatment of eye disorders based on neoangiogenesis

Publications (3)

Publication Number Publication Date
JP2013528607A JP2013528607A (ja) 2013-07-11
JP2013528607A5 JP2013528607A5 (enExample) 2014-06-26
JP5990511B2 true JP5990511B2 (ja) 2016-09-14

Family

ID=44276158

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2013511702A Expired - Fee Related JP5990511B2 (ja) 2010-05-28 2011-05-27 血管新生に基づく眼障害の処置のための抗ｃｄ１６０特異的抗体

Country Status (11)

Country Link
US (2) US9045544B2 (enExample)
EP (1) EP2575881B1 (enExample)
JP (1) JP5990511B2 (enExample)
KR (1) KR101847572B1 (enExample)
CN (2) CN102892432A (enExample)
BR (1) BR112012030318A2 (enExample)
CA (1) CA2796312C (enExample)
DK (1) DK2575881T3 (enExample)
ES (1) ES2606627T3 (enExample)
PL (1) PL2575881T3 (enExample)
WO (1) WO2011147984A1 (enExample)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10561707B2 (en) * 2013-09-08 2020-02-18 Technion Research And Development Foundation Ltd. Semaphorin 3C variants, compositions comprising said variants and methods of use thereof in treating eye diseases
WO2015168619A1 (en) * 2014-05-02 2015-11-05 Mayo Foundation For Medical Education And Research Individualized treatment of eye disease
US9840553B2 (en) 2014-06-28 2017-12-12 Kodiak Sciences Inc. Dual PDGF/VEGF antagonists
WO2017117464A1 (en) 2015-12-30 2017-07-06 Kodiak Sciences Inc. Antibodies and conjugates thereof
BR112019008345A8 (pt) * 2016-10-25 2023-03-07 Inst Nat Sante Rech Med Anticorpos monoclonais ligados à isoforma transmembrana cd160
FR3061716B1 (fr) * 2017-01-06 2019-05-17 Elsalys Biotech Nouveaux composes ciblant le cd160 humain
JP2020532586A (ja) * 2017-08-31 2020-11-12 シンガポール ヘルス サービシーズ プライベート リミテッド 網膜血管性疾患の処置のためのａｎｇｉｏ−３
BR112020017872A2 (pt) 2018-03-02 2020-12-22 Kodiak Sciences Inc. Anticorpos de il-6 e construtos de fusão e conjugados dos mesmos
WO2021072265A1 (en) 2019-10-10 2021-04-15 Kodiak Sciences Inc. Methods of treating an eye disorder
WO2021138409A2 (en) * 2019-12-31 2021-07-08 Medstar Health, Inc. Anti-cd160 binding molecules for treating diseases
CA3187272A1 (en) 2020-10-08 2022-04-14 Thorsten Ross Trispecific binders
EP4376958A1 (en) 2021-07-30 2024-06-05 Affimed GmbH Duplexbodies
JP2025532464A (ja) 2022-09-15 2025-10-01 アビディキュア アイピー ビー．ブイ． Ｎｋ細胞の腫瘍標的化のための多重特異性抗原結合タンパク質及びその使用
WO2025191136A1 (en) 2024-03-15 2025-09-18 Avidicure Ip B.V. Muteins of 4-1bb ligand extracellular domain, fusion proteins comprising the same and uses thereof
WO2025191133A1 (en) 2024-03-15 2025-09-18 Avidicure Ip B.V. Il-21 muteins, fusion proteins comprising the same and uses thereof

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3785186T2 (de) 1986-09-02 1993-07-15 Enzon Lab Inc Bindungsmolekuele mit einzelpolypeptidkette.
AU3178993A (en) 1991-11-25 1993-06-28 Enzon, Inc. Multivalent antigen-binding proteins
EP0628078B1 (en) 1992-12-11 1999-12-08 The Dow Chemical Company Multivalent single chain antibodies
AU5253898A (en) 1996-11-12 1998-06-03 Dana-Farber Cancer Institute Recombinant by55 and nucleic acids encoding same
US6884879B1 (en) 1997-04-07 2005-04-26 Genentech, Inc. Anti-VEGF antibodies
FR2794977B1 (fr) * 1999-06-18 2003-10-31 Commissariat Energie Atomique Utilisation de compositions contenant des formes solubles d'hla-g dans le traitement de pathologies inflammatoires de la peau, et leur procede d'obtention
EP1626059A1 (en) 2004-08-09 2006-02-15 Institut National De La Sante Et De La Recherche Medicale (Inserm) Angiogenic and immunologic applications of anti-CD160 specific compounds obtainable from mAb CL1-R2
JP2009525282A (ja) * 2006-01-30 2009-07-09 （オーエスアイ）アイテツク・インコーポレーテツド 血管新生疾患の治療のための組み合わせ療法
AR062239A1 (es) 2007-08-07 2008-10-22 Civil De Estudios Superiores A Composicion farmaceutica sinergica util para inhibir la neovascularizacion (angiogenesis) corneal y retinal, y de otros organos, en un humano o animal

Also Published As

Publication number Publication date
KR20130086548A (ko) 2013-08-02
ES2606627T3 (es) 2017-03-24
ES2606627T8 (es) 2017-06-09
DK2575881T3 (en) 2017-01-09
US10208124B2 (en) 2019-02-19
CA2796312A1 (en) 2011-12-01
KR101847572B1 (ko) 2018-05-24
US20150344572A1 (en) 2015-12-03
JP2013528607A (ja) 2013-07-11
CN107648605A (zh) 2018-02-02
US9045544B2 (en) 2015-06-02
EP2575881B1 (en) 2016-09-14
CN102892432A (zh) 2013-01-23
US20130122006A1 (en) 2013-05-16
WO2011147984A1 (en) 2011-12-01
PL2575881T3 (pl) 2018-06-29
BR112012030318A2 (pt) 2017-06-20
EP2575881A1 (en) 2013-04-10
CA2796312C (en) 2020-11-03

Similar Documents

Publication Publication Date Title
JP5990511B2 (ja) 血管新生に基づく眼障害の処置のための抗ｃｄ１６０特異的抗体
Kim et al. FcRn receptor-mediated pharmacokinetics of therapeutic IgG in the eye
CA2850824C (en) Treatment of ocular disease
US9512224B2 (en) Use of semaphorin-4D binding molecules for treatment of atherosclerosis
JP2022058369A (ja) アルツハイマー病治療方法
MX2008013211A (es) Uso de anticuerpos de il-1 para el tratamiento de trastornos oftalmicos.
TW201836646A (zh) 治療與血管生成及血管新生相關病症的方法
US20110110932A1 (en) Combination treatment for ocular diseases
JP2019201655A (ja) 神経学的疾患又は神経変性疾患に有用な新規抗体
US20220251193A1 (en) Semaphorin 3a antibodies and uses thereof
CN114901313B (zh) 急性期的视神经脊髓炎的预防或治疗剂
CN113645994A (zh) 使用色素上皮衍生因子(pedf)治疗疾病的方法
WO2025036488A9 (en) Methods of treating age-related macular degeneration and diabetic macular edema
US11447568B2 (en) Methods and compositions for the treatment of ocular diseases and disorders
TW202532435A (zh) 治療新生血管性眼疾之方法
CN119656311A (zh) 痴呆症的预防或治疗剂

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20140508

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20140508

RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20150305

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20150623

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20150914

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20151022

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20160209

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20160421

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20160802

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20160815

R150 Certificate of patent or registration of utility model

Ref document number: 5990511

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

LAPS Cancellation because of no payment of annual fees